Cargando…
Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY
BACKGROUND: While the vaccines against COVID-19 are highly effective, COVID-19 vaccine breakthrough is possible despite being fully vaccinated. With SARS-CoV-2 variants still circulating, describing the characteristics of individuals who have experienced COVID-19 vaccine breakthroughs could be hugel...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255436/ https://www.ncbi.nlm.nih.gov/pubmed/35791013 http://dx.doi.org/10.1186/s12916-022-02422-0 |
_version_ | 1784740920409718784 |
---|---|
author | Green, Amelia Curtis, Helen Hulme, William Williamson, Elizabeth McDonald, Helen Bhaskaran, Krishnan Rentsch, Christopher Schultze, Anna MacKenna, Brian Mahalingasivam, Viyaasan Tomlinson, Laurie Walker, Alex Fisher, Louis Massey, Jon Andrews, Colm Hopcroft, Lisa Morton, Caroline Croker, Richard Morley, Jessica Mehrkar, Amir Bacon, Seb Evans, David Inglesby, Peter Hickman, George Ward, Tom Davy, Simon Mathur, Rohini Tazare, John Eggo, Rosalind Wing, Kevin Wong, Angel Forbes, Harriet Bates, Chris Cockburn, Jonathan Parry, John Hester, Frank Harper, Sam Douglas, Ian Evans, Stephen Smeeth, Liam Goldacre, Ben |
author_facet | Green, Amelia Curtis, Helen Hulme, William Williamson, Elizabeth McDonald, Helen Bhaskaran, Krishnan Rentsch, Christopher Schultze, Anna MacKenna, Brian Mahalingasivam, Viyaasan Tomlinson, Laurie Walker, Alex Fisher, Louis Massey, Jon Andrews, Colm Hopcroft, Lisa Morton, Caroline Croker, Richard Morley, Jessica Mehrkar, Amir Bacon, Seb Evans, David Inglesby, Peter Hickman, George Ward, Tom Davy, Simon Mathur, Rohini Tazare, John Eggo, Rosalind Wing, Kevin Wong, Angel Forbes, Harriet Bates, Chris Cockburn, Jonathan Parry, John Hester, Frank Harper, Sam Douglas, Ian Evans, Stephen Smeeth, Liam Goldacre, Ben |
collection | PubMed |
description | BACKGROUND: While the vaccines against COVID-19 are highly effective, COVID-19 vaccine breakthrough is possible despite being fully vaccinated. With SARS-CoV-2 variants still circulating, describing the characteristics of individuals who have experienced COVID-19 vaccine breakthroughs could be hugely important in helping to determine who may be at greatest risk. METHODS: With the approval of NHS England, we conducted a retrospective cohort study using routine clinical data from the OpenSAFELY-TPP database of fully vaccinated individuals, linked to secondary care and death registry data and described the characteristics of those experiencing COVID-19 vaccine breakthroughs. RESULTS: As of 1st November 2021, a total of 15,501,550 individuals were identified as being fully vaccinated against COVID-19, with a median follow-up time of 149 days (IQR: 107–179). From within this population, a total of 579,780 (<4%) individuals reported a positive SARS-CoV-2 test. For every 1000 years of patient follow-up time, the corresponding incidence rate (IR) was 98.06 (95% CI 97.93–98.19). There were 28,580 COVID-19-related hospital admissions, 1980 COVID-19-related critical care admissions and 6435 COVID-19-related deaths; corresponding IRs 4.77 (95% CI 4.74–4.80), 0.33 (95% CI 0.32–0.34) and 1.07 (95% CI 1.06–1.09), respectively. The highest rates of breakthrough COVID-19 were seen in those in care homes and in patients with chronic kidney disease, dialysis, transplant, haematological malignancy or who were immunocompromised. CONCLUSIONS: While the majority of COVID-19 vaccine breakthrough cases in England were mild, some differences in rates of breakthrough cases have been identified in several clinical groups. While it is important to note that these findings are simply descriptive and cannot be used to answer why certain groups have higher rates of COVID-19 breakthrough than others, the emergence of the Omicron variant of COVID-19 coupled with the number of positive SARS-CoV-2 tests still occurring is concerning and as numbers of fully vaccinated (and boosted) individuals increases and as follow-up time lengthens, so too will the number of COVID-19 breakthrough cases. Additional analyses, to assess vaccine waning and rates of breakthrough COVID-19 between different variants, aimed at identifying individuals at higher risk, are needed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02422-0. |
format | Online Article Text |
id | pubmed-9255436 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-92554362022-07-06 Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY Green, Amelia Curtis, Helen Hulme, William Williamson, Elizabeth McDonald, Helen Bhaskaran, Krishnan Rentsch, Christopher Schultze, Anna MacKenna, Brian Mahalingasivam, Viyaasan Tomlinson, Laurie Walker, Alex Fisher, Louis Massey, Jon Andrews, Colm Hopcroft, Lisa Morton, Caroline Croker, Richard Morley, Jessica Mehrkar, Amir Bacon, Seb Evans, David Inglesby, Peter Hickman, George Ward, Tom Davy, Simon Mathur, Rohini Tazare, John Eggo, Rosalind Wing, Kevin Wong, Angel Forbes, Harriet Bates, Chris Cockburn, Jonathan Parry, John Hester, Frank Harper, Sam Douglas, Ian Evans, Stephen Smeeth, Liam Goldacre, Ben BMC Med Research Article BACKGROUND: While the vaccines against COVID-19 are highly effective, COVID-19 vaccine breakthrough is possible despite being fully vaccinated. With SARS-CoV-2 variants still circulating, describing the characteristics of individuals who have experienced COVID-19 vaccine breakthroughs could be hugely important in helping to determine who may be at greatest risk. METHODS: With the approval of NHS England, we conducted a retrospective cohort study using routine clinical data from the OpenSAFELY-TPP database of fully vaccinated individuals, linked to secondary care and death registry data and described the characteristics of those experiencing COVID-19 vaccine breakthroughs. RESULTS: As of 1st November 2021, a total of 15,501,550 individuals were identified as being fully vaccinated against COVID-19, with a median follow-up time of 149 days (IQR: 107–179). From within this population, a total of 579,780 (<4%) individuals reported a positive SARS-CoV-2 test. For every 1000 years of patient follow-up time, the corresponding incidence rate (IR) was 98.06 (95% CI 97.93–98.19). There were 28,580 COVID-19-related hospital admissions, 1980 COVID-19-related critical care admissions and 6435 COVID-19-related deaths; corresponding IRs 4.77 (95% CI 4.74–4.80), 0.33 (95% CI 0.32–0.34) and 1.07 (95% CI 1.06–1.09), respectively. The highest rates of breakthrough COVID-19 were seen in those in care homes and in patients with chronic kidney disease, dialysis, transplant, haematological malignancy or who were immunocompromised. CONCLUSIONS: While the majority of COVID-19 vaccine breakthrough cases in England were mild, some differences in rates of breakthrough cases have been identified in several clinical groups. While it is important to note that these findings are simply descriptive and cannot be used to answer why certain groups have higher rates of COVID-19 breakthrough than others, the emergence of the Omicron variant of COVID-19 coupled with the number of positive SARS-CoV-2 tests still occurring is concerning and as numbers of fully vaccinated (and boosted) individuals increases and as follow-up time lengthens, so too will the number of COVID-19 breakthrough cases. Additional analyses, to assess vaccine waning and rates of breakthrough COVID-19 between different variants, aimed at identifying individuals at higher risk, are needed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02422-0. BioMed Central 2022-07-05 /pmc/articles/PMC9255436/ /pubmed/35791013 http://dx.doi.org/10.1186/s12916-022-02422-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Green, Amelia Curtis, Helen Hulme, William Williamson, Elizabeth McDonald, Helen Bhaskaran, Krishnan Rentsch, Christopher Schultze, Anna MacKenna, Brian Mahalingasivam, Viyaasan Tomlinson, Laurie Walker, Alex Fisher, Louis Massey, Jon Andrews, Colm Hopcroft, Lisa Morton, Caroline Croker, Richard Morley, Jessica Mehrkar, Amir Bacon, Seb Evans, David Inglesby, Peter Hickman, George Ward, Tom Davy, Simon Mathur, Rohini Tazare, John Eggo, Rosalind Wing, Kevin Wong, Angel Forbes, Harriet Bates, Chris Cockburn, Jonathan Parry, John Hester, Frank Harper, Sam Douglas, Ian Evans, Stephen Smeeth, Liam Goldacre, Ben Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY |
title | Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY |
title_full | Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY |
title_fullStr | Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY |
title_full_unstemmed | Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY |
title_short | Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY |
title_sort | describing the population experiencing covid-19 vaccine breakthrough following second vaccination in england: a cohort study from opensafely |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255436/ https://www.ncbi.nlm.nih.gov/pubmed/35791013 http://dx.doi.org/10.1186/s12916-022-02422-0 |
work_keys_str_mv | AT describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT greenamelia describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT curtishelen describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT hulmewilliam describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT williamsonelizabeth describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT mcdonaldhelen describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT bhaskarankrishnan describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT rentschchristopher describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT schultzeanna describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT mackennabrian describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT mahalingasivamviyaasan describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT tomlinsonlaurie describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT walkeralex describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT fisherlouis describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT masseyjon describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT andrewscolm describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT hopcroftlisa describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT mortoncaroline describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT crokerrichard describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT morleyjessica describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT mehrkaramir describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT baconseb describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT evansdavid describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT inglesbypeter describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT hickmangeorge describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT wardtom describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT davysimon describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT mathurrohini describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT tazarejohn describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT eggorosalind describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT wingkevin describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT wongangel describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT forbesharriet describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT bateschris describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT cockburnjonathan describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT parryjohn describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT hesterfrank describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT harpersam describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT douglasian describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT evansstephen describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT smeethliam describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely AT goldacreben describingthepopulationexperiencingcovid19vaccinebreakthroughfollowingsecondvaccinationinenglandacohortstudyfromopensafely |